Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Receivables - NetReceivables - Other
Ratios

Marker Therapeutics (MRKR) Leases (2019 - 2023)

Marker Therapeutics (MRKR) has disclosed Leases for 5 consecutive years, with $5.3 million as the latest value for Q1 2023.

  • On a quarterly basis, Leases fell 44.52% to $5.3 million in Q1 2023 year-over-year; TTM through Mar 2023 was $5.3 million, a 44.52% decrease, with the full-year FY2022 number at $5.5 million, down 44.08% from a year prior.
  • Leases was $5.3 million for Q1 2023 at Marker Therapeutics, down from $5.5 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $11.1 million in Q3 2020 to a low of $300000.0 in Q2 2020.
  • A 5-year average of $5.9 million and a median of $5.6 million in 2022 define the central range for Leases.
  • Peak YoY movement for Leases: plummeted 45.2% in 2020, then surged 3333.33% in 2021.
  • Marker Therapeutics' Leases stood at $455174.0 in 2019, then soared by 2282.41% to $10.8 million in 2020, then fell by 9.63% to $9.8 million in 2021, then crashed by 44.08% to $5.5 million in 2022, then fell by 2.8% to $5.3 million in 2023.
  • Per Business Quant, the three most recent readings for MRKR's Leases are $5.3 million (Q1 2023), $5.5 million (Q4 2022), and $5.6 million (Q3 2022).